X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals (Nasdaq: XFOR) granted inducement equity awards to new employees effective August 31, 2026 under its 2019 Inducement Equity Incentive Plan.

Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) granted inducement equity awards to new employees effective August 31, 2026 under its 2019 Inducement Equity Incentive Plan. According to X4 Pharmaceuticals, the awards are stock options to purchase an aggregate of 50,000 common shares at an exercise price of $4.04, equal to the closing price on the grant date, with a ten-year term.

Each option vests over four years: 25% after 12 months and the remainder monthly over the next 36 months, subject to continued employment. The grants were approved by the board’s Compensation Committee in line with Nasdaq Listing Rule 5635(c)(4). X4 is also advancing mavorixafor (XOLREMDI) for rare hematology diseases, including a global Phase 3 4WARD trial in chronic neutropenic disorders.

Argus Sep 2 session

-0.74% close to close Open Argus

Details

News Market Reaction – XFOR

On Sep 2, the first trading day after this news, XFOR closed 0.74% below the previous close.

Data tracked by StockTitan Argus for the Sep 2 session.

Key Figures

Grant Effective Date: August 31, 2026 Option Shares: 50,000 shares Option Term: 10 years +4 more

Grant Effective Date

August 31, 2026

Inducement awards

Option Shares

50,000 shares

Aggregate common-stock options granted to new employees

Option Term

10 years

Inducement options

Exercise Price

$4.04 per share

Equal to the August 31, 2026 closing price

Vesting Period

4 years

Subject to continued employment

Initial Vesting

25%

Shares vest after 12 months

Remaining Vesting

36 months

Monthly vesting after the initial 12-month period

Historical Context

5 past events · Latest: Aug 06

5 events

1. Aug 06

   earnings report

   24h Move

   +11.3%

   Second-quarter results and corporate update were followed by a positive 24-hour reaction.

2. Aug 03

   inducement grants

   24h Move

   +4.9%

   New-employee options covering 12,000 shares preceded a positive 24-hour reaction.

3. Jul 07

   inducement grants

   24h Move

   +0.5%

   New-employee options covering 750,000 shares preceded a positive 24-hour reaction.

4. Jul 01

   board appointment

   24h Move

   -12.5%

   Kelly Gold joined the board and Audit Committee before a negative 24-hour reaction.

5. Jun 01

   inducement grants

   24h Move

   -1.7%

   New-employee options covering 160,000 shares preceded a negative 24-hour reaction.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), cxcr4 antagonist, phase 3 clinical trial, fast track designation

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

cxcr4 antagonist medical

"mavorixafor, an orally available CXCR4 antagonist"

A CXCR4 antagonist is a medicine that blocks a specific cell surface receptor called CXCR4, stopping signals that guide cell movement and survival. Think of it like putting a padlock on a door that cancer cells or immune cells use to travel and hide; this can slow tumor spread, help release stem cells for transplant, or interfere with viruses. For investors, drugs using this mechanism can create clear clinical milestones, niche market opportunities, and regulatory risks tied to trial results.

phase 3 clinical trial medical

"conducting a global, pivotal Phase 3 clinical trial"

A phase 3 clinical trial is a large-scale study that tests a new medical treatment or drug to determine if it is safe and effective for widespread use. It often involves hundreds or thousands of participants and compares the new treatment to existing options or a placebo. For investors, the results of this phase are crucial, as successful outcomes can lead to regulatory approval and commercial success, while failures may halt development.

fast track designation regulatory

"FDA has granted Fast Track designation to mavorixafor"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on August 31, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 50,000 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.

The options have a ten-year term and an exercise price of $4.04 per share, which is equal to the closing price of X4’s common stock on August 31, 2026. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee’s continued employment with X4 on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.

About X4 Pharmaceuticals

X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is approved in the U.S. and EU as XOLREMDI® for patients with WHIM syndrome. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.

X4 Investor Contact:
Remy Bernarda
Jenny Kobin
IR Advisory Solutions
ir@x4pharma.com

Source: X4 Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement grants did X4 Pharmaceuticals (XFOR) announce on September 1, 2026?

X4 Pharmaceuticals announced inducement stock option grants covering 50,000 shares of common stock for new employees. According to X4 Pharmaceuticals, these options were issued under the 2019 Inducement Equity Incentive Plan as material inducements to employment, consistent with Nasdaq Listing Rule 5635(c)(4).

What are the key terms of the new X4 Pharmaceuticals (XFOR) inducement stock options?

The inducement options have a ten-year term and a $4.04 exercise price per share. According to X4 Pharmaceuticals, each grant vests over four years, with 25% after 12 months and the remaining 75% vesting monthly over the subsequent 36 months, subject to continued employment.

How do the X4 Pharmaceuticals (XFOR) inducement options vest for new employees?

Each inducement option vests over a four-year schedule tied to continued employment at X4. According to X4 Pharmaceuticals, 25% of the shares vest after 12 months, and the remaining 75% vest in equal monthly installments during the following 36 months.

Under which plan and Nasdaq rule were the X4 Pharmaceuticals (XFOR) inducement awards granted?

The inducement awards were granted under the 2019 Inducement Equity Incentive Plan and Nasdaq Rule 5635(c)(4). According to X4 Pharmaceuticals, this plan is used exclusively for equity awards to individuals not previously employed by the company, as material inducements to joining.

What is X4 Pharmaceuticals’ lead therapy mavorixafor (XOLREMDI) mentioned in the XFOR inducement grant news?

Mavorixafor, branded as XOLREMDI, is an orally available CXCR4 antagonist for WHIM syndrome. According to X4 Pharmaceuticals, it is approved in the U.S. and EU, and is being studied in the global Phase 3 4WARD trial in chronic neutropenic disorders.

What clinical program is X4 Pharmaceuticals (XFOR) running alongside its September 2026 inducement grants?

X4 is conducting the global, pivotal Phase 3 4WARD trial evaluating mavorixafor in chronic neutropenic disorders. According to X4 Pharmaceuticals, the U.S. FDA has granted Fast Track designation to mavorixafor for treating chronic neutropenia, reflecting regulatory support for its development.